In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceCurrent perspectives on HIV-1 antiretroviral drug resistancePractical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewNovel therapeutic strategies targeting HIV integraseStructural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of ActionMight dolutegravir be part of a functional cure for HIV?Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsResistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitorsDolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kineticsNon-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cellsContribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyA novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.Molecular modeling study on the allosteric inhibition mechanism of HIV-1 integrase by LEDGF/p75 binding site inhibitors.Dolutegravir: clinical efficacy and role in HIV therapy.Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyPharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.New first and second generation inhibitors of human immunodeficiency virus-1 integrase.Rapid screening of HIV reverse transcriptase and integrase inhibitors.ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileHIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integraseDolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionIn vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2The role of dolutegravir in the management of HIV infectionHIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesInfluence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.Role of raltegravir in the management of HIV-1 infection.Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched ControlsRaltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.
P2860
Q24628743-B2459958-7CD6-4510-9CC7-7B9D09BA2E2BQ26801286-043493A3-39F9-4517-9E7F-837EFF1CFC6EQ26852626-3F5CAE8A-4004-421B-97CB-135922C1FBE8Q26853055-FDD7A4D3-36D4-427D-B65F-2AC289ADEBCAQ27003960-2EF48A47-875D-41C1-962C-A3DB6D5C9A42Q27670616-23ED29AE-F96A-4609-A0C7-8017E3A8856FQ27678745-D894865D-012D-4DF2-B8A1-92B77E4814CAQ28071420-3E544388-9870-4789-ADCC-9079CCAE33F2Q28077053-FCD707A5-8784-4B7C-8D24-4B65E87B917CQ28533830-5FEB02ED-AFA6-45B3-AF8C-81C5F606B371Q28534464-2FD6C9D4-D01A-4936-ACDE-E1AB20511B98Q28536951-5D766C7C-89D6-4203-914A-1A6117C0BCEAQ28541754-262F0F6F-9DEA-4EFB-BA43-7D39AD48EDEFQ30429621-64AA6196-1EFD-46BF-A9B5-049071DACBCAQ31153312-0118D121-8441-48A7-96AE-F061095C0679Q33725024-198A8A53-E101-44C2-A037-114ABEC9AD52Q33880221-239180F7-3A27-496C-8BE2-7CB767C9A267Q33911400-83C19050-4999-4915-BBE1-C467F57CBF37Q33963958-2F87F2DC-BE7F-460F-9558-F47CBB37254BQ34059575-43678D36-0ADF-4F8A-9B50-D2AA9E408ABFQ34186375-EE62D0BB-CCE6-4EE0-86A1-6B7CBA274177Q34193340-DB92237E-689E-4714-A7B0-5FDA954F00B9Q34202181-8DB45B77-0760-4B1B-9F9C-5B2D4B105A4AQ34316681-1F312EA2-EDB3-45C7-BF22-E4EAFEE63DA6Q34540677-E1A7A058-EB8B-43DE-BC29-A52E171569DBQ34597650-513EB1A6-B434-4C2B-957B-E8EF07F01262Q34726183-87D05786-7646-44D2-A619-A952F9861274Q34736194-EABA0D96-2536-4D7A-94BE-5B213EE8FA3AQ34976284-A4964593-9291-481C-919D-E2694BB94335Q35083423-1370E5AC-B05D-4D3F-B2FE-90690377F4D9Q35121450-CE66F713-5CD0-46C2-BFCC-882DECD0F84DQ35134947-17076A7C-C43C-4347-B202-1EC30822FFB4Q35169003-354F5B09-BE97-4E68-AC65-F29BF27C24C4Q35432739-1E203634-5555-4168-B99E-9EDBA5CAA138Q35540399-73C87EE4-6D64-4665-9EC0-1E6658D97838Q35557318-44F7F9E9-CB90-4ECB-B26D-AAF579F4DC6CQ35741981-53C72E3E-13F2-4931-95BA-5F7F4337D6AAQ35789343-BD8CD2C4-C5CB-46B2-BE9D-DDB1B90F7AF8Q35806381-8C392499-0D4A-483E-AC89-F546302B0520Q36072494-47EB3999-9873-4540-91A3-7B2286514296
P2860
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
In Vitro antiretroviral proper ...... ation HIV integrase inhibitor.
@en
In Vitro antiretroviral proper ...... ation HIV integrase inhibitor.
@nl
type
label
In Vitro antiretroviral proper ...... ation HIV integrase inhibitor.
@en
In Vitro antiretroviral proper ...... ation HIV integrase inhibitor.
@nl
prefLabel
In Vitro antiretroviral proper ...... ation HIV integrase inhibitor.
@en
In Vitro antiretroviral proper ...... ation HIV integrase inhibitor.
@nl
P2093
P2860
P356
P1476
In Vitro antiretroviral proper ...... ation HIV integrase inhibitor.
@en
P2093
Akemi Suyama-Kagitani
Akihiko Sato
Brian A Johns
Chiaki Wakasa-Morimoto
Edward P Garvey
Kevin W Brown
Mark R Underwood
Masanori Kobayashi
Richard J Hazen
Robert Ferris
P2860
P304
P356
10.1128/AAC.01209-10
P407
P577
2010-11-29T00:00:00Z